Goldman Sachs Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raises the price target from $66 to $74.
August 09, 2024 | 11:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst Salveen Richter maintains a Buy rating on Apellis Pharmaceuticals and raises the price target from $66 to $74.
The Buy rating and increased price target from a reputable analyst at Goldman Sachs are likely to positively influence investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100